Vascular endothelial growth factor-X
AssigneeJanssen Pharmaceutica NV
InventorsRobert D. Gordon, Jörg J. Sprengel, Jeffrey R. Yon, Josiena J. H. Dijkmans, Anna Gosiewska, Sridevi N. Dhanaraj, Jean Xu
Life of this patent
Estimating the term…
Abstract
There is provided a novel vascular endothelial growth factor, herein designated VEGF-X, in addition to the nucleic acid molecule encoding it, a host cell transformed with said vector and compounds which inhibit or enhance angiogenesis. Also provided is the sequence of a CUB domain present in the sequence of VEGF-X which domain itself prevents angiogenesis and which is used to treat diseases associated with inappropriate vascularisation or angiogenesis.
Claims7
An isolated nucleic acid molecule encoding a polypeptide having a CUB domain, wherein said polypeptide has anti-proliferative activity and consists essentially of the amino acid sequence of SEQ ID NO:26.
An isolated nucleic acid molecule encoding a polypeptide having a CUB domain, said polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:27.
An isolated nucleic acid molecule encoding a polypeptide that has anti-proliferative activity and consists essentially of the amino acid sequence of SEQ ID NO:26 for use as a medicament.
Dependencies are inferred from the claim text.